Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Primary Sjogren’s Disease with Moderate to Severe Systemic Activity
2025-520831-18-00Phase 2Authorised
- Sponsor
- Immunovant, Inc.
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing IMVT-1402 arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in clinESSDAI score at Week 24. Planned start Dec 2025; status: authorised.
02
Drugs
IMVT-1402
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2025-520831-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520831-18-00.